YAR Stock Analysis: Yara International ASA | OL
Agricultural Inputs | OL, Norway | Market Cap: 116.180m NOK | 12M Return: 18.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 207M
EPS Trend: 73.3%
Qual. Beats: -1
Rev. Trend: 14.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Yara International ASA is a Norwegian crop nutrition and industrial chemicals company that operates globally, with a presence in Europe, Africa, Asia, the Americas, and Oceania. Founded in 1905 and headquartered in Oslo, the company manufactures and sells a wide range of fertilizer products, including ammonium-, urea-, and nitrate-based fertilizers, as well as compound fertilizers containing nitrogen, phosphorus, and potassium, and specialty offerings such as biostimulants, organic-based fertilizers, and foliar and fertigation solutions.
Beyond its core fertilizer portfolio, Yara has built an extensive digital agriculture ecosystem, offering tools and platforms such as YaraFX Insight, N-sensors, N-Tester, Atfarm, YaraPlus, and Yara FarmCare that help farmers and retailers optimize crop nutrition and farm management decisions. Its products are marketed under well-known brands including YaraBela, YaraMila, YaraLiva, YaraVita, and YaraTera. The company also serves industrial customers with ammonia and related chemical solutions.
As a large-cap player in the Materials sector (Fertilizers & Agricultural Chemicals sub-industry), Yara operates in a globally consolidated industry where scale, access to low-cost natural gas for ammonia production, and distribution networks are key competitive advantages. The company also sells through an e-commerce platform, reflecting the broader digitization trend in agricultural input distribution.
- European natural gas prices pressure nitrogen production margins
- Premium specialty fertilizer mix expands product margins
- Green ammonia investments increase near-term capital spending
| Net Income: 1.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 19.86% < 20% (prev 17.60%; Δ 2.26% < -1%) |
| CFO/TA 0.27 > 3% & CFO 4.65b > Net Income 1.53b |
| Net Debt (-165.0m) to EBITDA (3.15b): -0.05 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (254.7m) vs 12m ago -0.00% < -2% |
| Gross Margin: 30.01% > 18% (prev 27.45%; Δ 2.56% > 0.5%) |
| Asset Turnover: 96.16% > 50% (prev 86.37%; Δ 9.80% > 0%) |
| Interest Coverage Ratio: 7.97 > 6 (EBIT TTM 2.06b / Interest Expense TTM 259.0m) |
| A: 0.19 (Total Current Assets 7.49b - Total Current Liabilities 4.21b) / Total Assets 17.5b |
| B: 0.62 (Retained Earnings 10.9b / Total Assets 17.5b) |
| C: 0.12 (EBIT TTM 2.06b / Avg Total Assets 17.2b) |
| D: 1.06 (Book Value of Equity 9.01b / Total Liabilities 8.47b) |
| Altman-Z'' = 5.19 = AAA |
| DSRI: 0.90 (Receivables 1.99b/1.94b, Revenue 16.5b/14.6b) |
| GMI: 0.91 (GM 27.45% / 30.01%) |
| AQI: 0.90 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.13 (Revenue 16.5b / 14.6b) |
| TATA: -0.18 (NI 1.53b - CFO 4.65b) / TA 17.5b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at NOK 437.80 with a total of 543,321 shares traded. Over the past week, the price has changed by -2.21%, over one month by +1.37%, over three months by -14.81% and over the past year by +18.43%.
Current recommended Stop Loss: 412.70 (which is 5.7% or 1.8 ATR below the current price).
Yara International ASA has no consensus analysts rating.
Market Cap USD = 12.1b (116b NOK * 0.1045 NOK.USD)
P/E Trailing = 7.876
P/E Forward = 7.8309
P/S = 7.0238
P/B = 1.3553
P/EG = 2.5338
Revenue TTM = 16.5b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 3.15b USD
Long Term Debt = 2.78b USD (from longTermDebt, last quarter)
Short Term Debt = 449.0m USD (from shortLongTermDebt, last quarter)
Debt = 540.0m USD (Leases only: 540.0m)
Net Debt = -165.0m USD (calculated: Debt 540.0m - CCE 705.0m)
Enterprise Value = 12.0b USD (12.1b + Debt 540.0m - CCE 705.0m)
Interest Coverage Ratio = 7.97 (Ebit TTM 2.06b / Interest Expense TTM 259.0m)
EV/FCF = 12.53x (Enterprise Value 12.0b / FCF TTM 956.0m)
FCF Yield = 7.98% (FCF TTM 956.0m / Enterprise Value 12.0b)
FCF Margin = 5.78% (FCF TTM 956.0m / Revenue TTM 16.5b)
Net Margin = 9.27% (Net Income TTM 1.53b / Revenue TTM 16.5b)
Gross Margin = 30.01% ((Revenue TTM 16.5b - Cost of Revenue TTM 11.6b) / Revenue TTM)
Gross Margin QoQ = 31.12% (prev 30.34%)
Tobins Q-Ratio = 0.68 (Enterprise Value 12.0b / Total Assets 17.5b)
Interest Expense / Debt = 47.96% (Interest Expense 259.0m / Debt 540.0m)
Taxrate = 22.53% (447.0m / 1.98b)
NOPAT = 1.60b (EBIT 2.06b * (1 - 22.53%))
Current Ratio = 1.78 (Total Current Assets 7.49b / Total Current Liabilities 4.21b)
Debt / Equity = 0.06 (Debt 540.0m / totalStockholderEquity, last quarter 9.01b)
Debt / EBITDA = -0.05 (Net Debt -165.0m / EBITDA 3.15b)
Debt / FCF = -0.17 (Net Debt -165.0m / FCF TTM 956.0m)
Total Stockholder Equity = 8.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.91% (Net Income 1.53b / Total Assets 17.5b)
RoE = 17.41% (Net Income TTM 1.53b / Total Stockholder Equity 8.81b)
RoCE = 17.81% (EBIT 2.06b / Capital Employed (Equity 8.81b + L.T.Debt 2.78b))
RoIC = 12.58% (NOPAT 1.60b / Invested Capital 12.7b)
WACC = 7.83% (E(12.1b)/V(12.7b) * Re(6.53%) + D(540.0m)/V(12.7b) * Rd(47.96%) * (1-Tc(0.23)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈824.8m ; Y1≈945.5m ; Y5≈1.39b
[DCF] Fair Price = 82.85 (EV 20.9b - Net Debt -165.0m = Equity 21.1b / Shares 254.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 73.25 | EPS CAGR: 138.6% | SUE: -3.74 | # QB: -1
Revenue Correlation: 14.88 | Revenue CAGR: 1.21% | SUE: -0.98 | # QB: -1
EPS current Quarter (2026-09-30): EPS=14.46 | Chg30d=-32.15% | Revisions=-40% | Analysts=5
EPS current Year (2026-12-31): EPS=60.19 | Chg30d=-12.03% | Revisions=+0% | GrowthEPS=+42.9% | GrowthRev=+11.5%
EPS next Year (2027-12-31): EPS=47.81 | Chg30d=+2.53% | Revisions=+0% | GrowthEPS=-20.6% | GrowthRev=-3.8%
[Analyst] Revisions Ratio: -10% (up=8, down=10)